Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer

曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制

基本信息

  • 批准号:
    10437778
  • 负责人:
  • 金额:
    $ 27.29万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract: The RAS-regulated RAFMEKERK MAP kinase pathway is a central pathway for pancreatic cancer initiation as 95% of pancreatic adenocarcinomas express mutationally activated KRAS. To date, however, targeting downstream components of KRAS signaling in clinical trials have not shown efficacy. Autophagy has also been shown to be important for pancreatic cancer tumorigenesis, however, clinical trials have been disappointing with chloroquine/hydroxychloroquine (4-aminoquinolones) treatment in conjunction with standard chemotherapy. We have recently demonstrated that combined inhibition of both MEK 1/2 and autophagy results in in vitro cytotoxicity and dramatic in vivo tumor regression in a recent publication in Nature Medicine, which was extended to a single pancreatic cancer patient with no therapeutic options left who demonstrated a dramatic tumor burden reduction of ~50% after 4 months of therapy of combined trametinib and hydroxychloroquine. Two Phase I/II clinical trials have resulted from the work and are either accruing or soon to open. The long-term goals of my research as a physician-scientist is to contribute a deeper mechanistic understating of KRAS signaling in pancreatic cancer and design successful clinical strategies to improve outcomes for one of the most treatment resistant human malignancies. The short-term goals of this K08 application are to understand the resistance mechanisms to trametinib and hydroxychloroquine to determine predictive biomarkers and how to overcome resistance. My immediate career goals over the next 5 years include updating and broadening my knowledge of cancer biology, becoming proficient in grant writing, accomplishing the AIMS outlined in this proposal, publishing the results, assisting in designing and executing clinical trials resulting from the work, securing grants, continued expansion of laboratory personnel, generating R01 applications, and establishing excellence in my clinical practice. My long term career goals include building an enterprise of investigations into the discovery of therapeutic targets for treating gastrointestinal malignancies, furthering the field of understanding of the role for autophagy in malignancy, and training the next generation of physicians and scientists. My mentors include Martin McMahon, PhD, G. Weldon Gilcrease III, MD and Ignacio Garrido-Laguna, MD, PhD. Dr. McMahon provides me with laboratory space and expertise in RAFMEKERK MAP kinase signaling, pre-clinical modeling and pancreatic cancer cell biology. Dr. Gilcrease is a GI Oncologist provides guidance with clinical responsibilities. Dr. Garrido-Laguna is a GI Oncologist with expertise in pancreatic cancer and clinical trials, who will advise in designing and executing anticipated clinical trials that will result from this body of work. In addition to these excellent mentors in basic science and clinical pursuits I will also have the support of the Preclinical Research Resource Core and collaboration with Courtney Scaife, MD and Jill Shea, PhD who will assist with preclinical model PDX establishment and testing. In summary I will have an excellent environment to further my career with guidance and support for basic science, translational science, and clinical investigation.
翻译后摘要:RAS调节的RAF-ERK-ERK-MAP激酶途径是胰腺癌的中心途径, 95%的胰腺癌表达突变激活的KRAS。然而,迄今为止, 在临床试验中靶向KRAS信号传导的下游组分没有显示出功效。自噬 也被证明对胰腺癌肿瘤发生很重要,然而,临床试验已经被证实, 氯喹/羟氯喹(4-氨基喹诺酮类)联合标准治疗令人失望 化疗我们最近已经证明,联合抑制MEK 1/2和自噬导致 体外细胞毒性和显著的体内肿瘤消退, 扩展到一个没有治疗选择的胰腺癌患者, 曲美替尼和羟氯喹联合治疗4个月后,肿瘤负荷降低约50%。两 I/II期临床试验已经从这项工作中产生,并且正在积累或即将开放。远景目标 作为一名物理学家,我的研究的一个重点是对KRAS信号的更深层次的机制性理解, 胰腺癌和设计成功的临床策略,以改善结果的最治疗之一, 耐药的人类恶性肿瘤。本K 08应用程序的短期目标是了解阻力 曲美替尼和羟氯喹的机制,以确定预测性生物标志物以及如何克服 阻力我在未来5年的职业目标包括更新和扩大我的知识, 癌症生物学,精通赠款写作,完成本提案中概述的AIMS,出版 结果,协助设计和执行临床试验的工作,获得赠款,继续 扩大实验室人员,生成R 01应用程序,并在我的临床实践中建立卓越 实践我的长期职业目标包括建立一个企业的调查发现 用于治疗胃肠道恶性肿瘤的治疗靶点,进一步了解 恶性肿瘤中的自噬,以及培养下一代医生和科学家。我的导师包括 Martin McMahon,PhD,G. Weldon Gilcrease III,医学博士和伊格纳西奥Garrido-Laguna,医学博士,博士。麦克马洪医生 为我提供了实验室空间和RAF ERK ERK MAP激酶信号传导,临床前 建模和胰腺癌细胞生物学。Gilcrease博士是一名GI肿瘤学家, 责任Garrido-Laguna博士是一名GI肿瘤学家,在胰腺癌和临床试验方面具有专业知识, 将建议在设计和执行预期的临床试验,将导致从这一机构的工作。此外 这些优秀的导师在基础科学和临床的追求,我也将支持临床前 研究资源核心和合作与考特尼斯凯夫,医学博士和吉尔谢伊,博士谁将协助 临床前模型PDX的建立和测试。总之,我将有一个很好的环境,以进一步我的 职业生涯与指导和支持基础科学,转化科学和临床研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Conan Kinsey其他文献

Conan Kinsey的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Conan Kinsey', 18)}}的其他基金

Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10055658
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10197024
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:
Resistance Mechanisms to Combined Trametinib and 4-aminoquinolones in the Inhibition of Pancreatic Cancer
曲美替尼联合 4-氨基喹诺酮类药物抑制胰腺癌的耐药机制
  • 批准号:
    10656403
  • 财政年份:
    2020
  • 资助金额:
    $ 27.29万
  • 项目类别:

相似国自然基金

基于Teach-back药学科普模式的慢阻肺患者吸入用药依从性及疗效研究
  • 批准号:
    2024KP61
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Quench-Back保护的超导螺线管磁体失超过程数值模拟研究
  • 批准号:
    51307073
  • 批准年份:
    2013
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
  • 批准号:
    2338816
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Continuing Grant
One-step reconstruction of plastic waste back to its constituent monomers (ONESTEP)
将塑料废物一步重建回其组成单体(ONESTEP)
  • 批准号:
    EP/Y003934/1
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Research Grant
On the origin of very massive back holes
关于巨大背洞的起源
  • 批准号:
    DP240101786
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Discovery Projects
Back to our roots: Re-activating Indigenous biocultural conservation
回到我们的根源:重新激活本土生物文化保护
  • 批准号:
    FT230100595
  • 财政年份:
    2024
  • 资助金额:
    $ 27.29万
  • 项目类别:
    ARC Future Fellowships
Collaborative Research: FuSe: Indium selenides based back end of line neuromorphic accelerators
合作研究:FuSe:基于硒化铟的后端神经形态加速器
  • 批准号:
    2328741
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Continuing Grant
Collaborative Research: NSFGEO-NERC: MEZCAL: Methods for Extending the horiZontal Coverage of the Amoc Latitudinally and back in time (MEZCAL)
合作研究:NSFGEO-NERC:MEZCAL:扩展 Amoc 纬度和时间回水平覆盖范围的方法 (MEZCAL)
  • 批准号:
    2409764
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
    Standard Grant
Relationships Between Pain-Related Psychological Factors, Gait Quality, and Attention in Chronic Low Back Pain
慢性腰痛中疼痛相关心理因素、步态质量和注意力之间的关系
  • 批准号:
    10679189
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
The Role of VEGF in the Development of Low Back Pain Following IVD Injury
VEGF 在 IVD 损伤后腰痛发展中的作用
  • 批准号:
    10668079
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
Psilocybin and Affective Function in Chronic Lower Back Pain and Depression
裸盖菇素与慢性腰痛和抑郁症的情感功能
  • 批准号:
    10626449
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
Brain Mechanisms of Chronic Low-Back Pain: Specificity and Effects of Aging and Sex
慢性腰痛的脑机制:衰老和性别的特异性和影响
  • 批准号:
    10657958
  • 财政年份:
    2023
  • 资助金额:
    $ 27.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了